Todos Medical Initiates MonkeyPox Diagnostic Case
Post# of 1418
(Total Views: 309)
Posted On: 08/23/2022 9:33:49 PM
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has initiated a MonkeyPox diagnostic case study series evaluating the potential for missed diagnosis among suspected MonkeyPox among non-gay male patient groups who have been unable to secure adequate testing to confirm their diagnosis, and who remain symptomatic up to 10 weeks. The first four enrollees in the case study series include three women and one man. The Company intends to work closely with the patients to evaluate multiple test articles for potential MonkeyPox viral reservoir and hopes to enroll sufficient numbers of patients to be able to ultimately validate different sample types as laboratory developed tests (LDTs). The Company remains open to accepting additional patients into its MonkeyPox case study series.
The Company also intends to work closely with Amerimmune to measure effects of MonkeyPox on the immune system. This data is expected to uniquely position Provista in the MonkeyPox testing space by providing not only insight on potential active and recent infection, but also in the area of potential viral reservoir driving longer-term symptoms and the development of immunity from infection, and potentially Jynneos vaccination. The Company will use data gathered from these patients to support the launch of a planned blood-based IgM/IgG laboratory developed to determine active or recent infection through blood, as well as a measure of immunity status.
Patients who have had challenges being definitively diagnosed with MonkeyPox, especially women and children, can contact Provista for potential enrollment in the MonkeyPox case study series at customerservice@provistadx.com.
https://investor.todosmedical.com/news-events...se-studies
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. has initiated a MonkeyPox diagnostic case study series evaluating the potential for missed diagnosis among suspected MonkeyPox among non-gay male patient groups who have been unable to secure adequate testing to confirm their diagnosis, and who remain symptomatic up to 10 weeks. The first four enrollees in the case study series include three women and one man. The Company intends to work closely with the patients to evaluate multiple test articles for potential MonkeyPox viral reservoir and hopes to enroll sufficient numbers of patients to be able to ultimately validate different sample types as laboratory developed tests (LDTs). The Company remains open to accepting additional patients into its MonkeyPox case study series.
The Company also intends to work closely with Amerimmune to measure effects of MonkeyPox on the immune system. This data is expected to uniquely position Provista in the MonkeyPox testing space by providing not only insight on potential active and recent infection, but also in the area of potential viral reservoir driving longer-term symptoms and the development of immunity from infection, and potentially Jynneos vaccination. The Company will use data gathered from these patients to support the launch of a planned blood-based IgM/IgG laboratory developed to determine active or recent infection through blood, as well as a measure of immunity status.
Patients who have had challenges being definitively diagnosed with MonkeyPox, especially women and children, can contact Provista for potential enrollment in the MonkeyPox case study series at customerservice@provistadx.com.
https://investor.todosmedical.com/news-events...se-studies
(1)
(0)